| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Prosaikogenin D exhibits anti-cancer activity, primarily through the inhibition of cancer cell proliferation. It also exerts anti-inflammatory, hepatoprotective, and immunomodulatory effects through the regulation of inflammatory mediators and cytokine production. Specifically, it has been shown to suppress the proliferation of A549 human lung adenocarcinoma cells. Unlike its C28-methyl ester analog (PrsDMe), Prosaikogenin D exhibits no nitric oxide (NO) inhibition in LPS-stimulated macrophages, enabling precise structure-activity correlation studies.
|
|---|---|
| ln Vitro |
Prosaikogenin D (20, 40, and 60 μg/mL) inhibits A549 cell growth, with an IC50 of 57.2 μg/mL[2].
In vitro studies have demonstrated that Prosaikogenin D suppresses the proliferation of A549 human lung adenocarcinoma cells. At concentrations of 20, 40, and 60 μg/mL, the compound inhibits A549 cell growth with a half-maximal inhibitory concentration (IC50) of 57.2 μg/mL. This anti-cancer activity is dose-dependent and has been confirmed in multiple studies. Prosaikogenin D shows zero NO inhibition in LPS-stimulated macrophages, in contrast to its active C28-methyl ester analog. |
| ln Vivo |
In vivo activity data for Prosaikogenin D have not been extensively documented in the available literature. Its anti-inflammatory, hepatoprotective, and immunomodulatory effects have been suggested based on its bioactivity profile. However, specific animal model studies evaluating its in vivo efficacy have not been reported. Further investigation is needed to confirm its systemic pharmacological effects.
|
| Enzyme Assay |
Specific protocols for enzyme or receptor binding assays for Prosaikogenin D have not been established in the literature. For triterpenoid saponins, typical binding studies involve assessing interactions with cell membrane components, as saponins are known to interact with cholesterol and membrane proteins. Binding affinity can be evaluated using surface plasmon resonance or isothermal titration calorimetry.
|
| Cell Assay |
Cytotoxicity assays against A549 cells are performed by culturing cells in 96-well plates and treating with Prosaikogenin D at concentrations of 20, 40, and 60 μg/mL. Cell viability is measured using standard colorimetric methods such as MTT or SRB assays to calculate inhibition rates and determine the IC50 value. The assay typically involves a 48-72 hour incubation period following compound treatment.
|
| Animal Protocol |
In vivo animal protocols for Prosaikogenin D have not been reported. For related saikosaponins, standard rodent models are used for evaluating anti-cancer efficacy, typically involving subcutaneous xenograft tumors in immunodeficient mice. Administration routes may include oral gavage or intraperitoneal injection, followed by monitoring of tumor growth and survival.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Prosaikogenin D, including absorption, distribution, metabolism, and excretion, have not been characterized. The compound has a molecular weight of 618.84 and a molecular formula of C36H58O8. It is typically stored as a powder at -20°C for up to 3 years and in solvent at -80°C for up to 1 year. As a saponin, it is likely to have limited oral bioavailability.
|
| Toxicity/Toxicokinetics |
Toxicological data for Prosaikogenin D are limited. As a research-use-only compound, it has not undergone formal safety assessment for human therapeutic applications. Saponins are known to exhibit hemolytic activity at high concentrations due to their membrane-disrupting effects. Standard handling precautions for laboratory chemicals should be observed.
|
| References | |
| Additional Infomation |
Reports indicate that Bupleurum contains prosapogenin D, and relevant data is available for reference.
Prosaikogenin D is a research-use-only compound. It is a natural product extracted from the roots of Bupleurum bicaule Helm with anti-cancer activity. Its anti-inflammatory, hepatoprotective, and immunomodulatory effects make it of interest for further exploration in drug development and integrative medicine. It is available from various chemical suppliers as a high-purity reference standard for natural product research. |
| Molecular Formula |
C36H58O8
|
|---|---|
| Exact Mass |
618.413
|
| CAS # |
103629-72-7
|
| PubChem CID |
101596922
|
| Appearance |
White to off-white solid
|
| LogP |
4.1
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
44
|
| Complexity |
1200
|
| Defined Atom Stereocenter Count |
14
|
| SMILES |
C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]2CC[C@]3([C@H]([C@]2(C)CO)CC[C@@]4([C@@H]3C=CC5=C6CC(CC[C@@]6([C@@H](C[C@]54C)O)CO)(C)C)C)C)O)O)O
|
| InChi Key |
UAUUFLADFXKYAU-WQPKRVEVSA-N
|
| InChi Code |
InChI=1S/C36H58O8/c1-20-27(40)28(41)29(42)30(43-20)44-26-11-12-32(4)23(33(26,5)18-37)10-13-34(6)24(32)9-8-21-22-16-31(2,3)14-15-36(22,19-38)25(39)17-35(21,34)7/h8-9,20,23-30,37-42H,10-19H2,1-7H3/t20-,23-,24-,25-,26+,27+,28+,29-,30+,32+,33+,34-,35-,36-/m1/s1
|
| Chemical Name |
(2R,3R,4S,5R,6R)-2-[[(3S,4R,4aR,6aR,6bS,8R,8aS,14aR,14bS)-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,14a-dodecahydropicen-3-yl]oxy]-6-methyloxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
